News & Trends - MedTech & Diagnostics
Out-of-pocket expenses double for Australians with private health insurance

Private health insurance (PHI) plays a crucial role in the Australian health system, with over 45% of the population currently holding PHI coverage. Despite this widespread uptake, a new study has revealed that Australians with PHI spend double the share of their disposable income on out-of-pocket medical expenses compared to those without coverage.
This raises questions about whether PHI is a good financial deal for the government as it incentivises PHI uptake to contribute to the funding and sustainability of the nation’s health system.
Independent studies commissioned by the Department of Health indicate that the Federal Government is approximately $1,400 better off for each person holding private health insurance, after considering the cost of the rebate, the foregone Medicare Levy Surcharge, and the reduction in burden on the public health system.
However, out-of-pocket expenses (OOPE) creates a policy concern if it requires a high share of income, particularly among low-income individuals who face trade-offs between healthcare and other essential goods and services.
Many PHI plans for hospital care use list prices that are lower than the hospital fee, covering only part of the costs. Consequently, OOPE is typically required for private hospital care, even when PHI and Medicare cover most of the expenses.
This suggests that PHI offers only limited protection against OOPE for individuals who require hospitalisation or use more healthcare services due to chronic conditions, while potentially offering other benefits such as choice of physician and reduced waiting times.
For lower-income individuals, “Out-of-pocket expenditure presents a significant burden, and Private health insurance does not appear to mitigate this burden. We therefore argue that, from an equity perspective, out-of-pocket expenditure is a policy concern in Australia, and our results suggest that Private health insurance does not appear to help solve it,” wrote the authors.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More